Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 39 | 2023 | 6773 | 2.050 |
Why?
|
| Occult Blood | 14 | 2023 | 176 | 1.740 |
Why?
|
| Early Detection of Cancer | 25 | 2023 | 3086 | 1.590 |
Why?
|
| Colonoscopy | 16 | 2023 | 1367 | 1.430 |
Why?
|
| Colonography, Computed Tomographic | 9 | 2021 | 169 | 0.950 |
Why?
|
| Mass Screening | 24 | 2023 | 5255 | 0.910 |
Why?
|
| Adenoma | 9 | 2020 | 2174 | 0.500 |
Why?
|
| Feces | 8 | 2021 | 1401 | 0.460 |
Why?
|
| Advisory Committees | 1 | 2016 | 775 | 0.410 |
Why?
|
| Models, Theoretical | 5 | 2020 | 3589 | 0.400 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2023 | 2020 | 0.390 |
Why?
|
| Preventive Health Services | 1 | 2016 | 575 | 0.390 |
Why?
|
| Models, Statistical | 7 | 2021 | 5102 | 0.380 |
Why?
|
| Direct Service Costs | 1 | 2010 | 62 | 0.370 |
Why?
|
| Cost-Benefit Analysis | 18 | 2023 | 5391 | 0.370 |
Why?
|
| Sigmoidoscopy | 4 | 2021 | 156 | 0.370 |
Why?
|
| Sensitivity and Specificity | 12 | 2021 | 14722 | 0.260 |
Why?
|
| Life Expectancy | 5 | 2021 | 1184 | 0.240 |
Why?
|
| Models, Economic | 2 | 2014 | 713 | 0.240 |
Why?
|
| Polyps | 1 | 2023 | 189 | 0.200 |
Why?
|
| Gallbladder Neoplasms | 1 | 2023 | 183 | 0.200 |
Why?
|
| Computer Simulation | 10 | 2020 | 6196 | 0.200 |
Why?
|
| Health Status Disparities | 3 | 2020 | 1797 | 0.200 |
Why?
|
| DNA, Neoplasm | 2 | 2019 | 1758 | 0.180 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 20822 | 0.180 |
Why?
|
| Ovarian Cysts | 1 | 2020 | 115 | 0.180 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 13102 | 0.170 |
Why?
|
| Time | 1 | 2020 | 542 | 0.160 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2019 | 84 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 3 | 2023 | 5256 | 0.160 |
Why?
|
| Ovarian Neoplasms | 3 | 2020 | 4838 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2019 | 1634 | 0.150 |
Why?
|
| Drug Therapy | 1 | 2019 | 497 | 0.140 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2018 | 186 | 0.140 |
Why?
|
| Health Care Costs | 5 | 2019 | 3209 | 0.140 |
Why?
|
| Aged, 80 and over | 14 | 2023 | 57776 | 0.140 |
Why?
|
| Medically Underserved Area | 1 | 2018 | 253 | 0.140 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2021 | 1683 | 0.130 |
Why?
|
| Humans | 55 | 2023 | 744343 | 0.120 |
Why?
|
| Aged | 24 | 2023 | 163280 | 0.120 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2018 | 484 | 0.120 |
Why?
|
| Immunoassay | 2 | 2014 | 752 | 0.110 |
Why?
|
| Middle Aged | 28 | 2023 | 213383 | 0.110 |
Why?
|
| Patient Compliance | 3 | 2014 | 2684 | 0.110 |
Why?
|
| Sex Factors | 5 | 2021 | 10397 | 0.110 |
Why?
|
| Incidental Findings | 1 | 2018 | 689 | 0.110 |
Why?
|
| Immunologic Tests | 1 | 2012 | 103 | 0.100 |
Why?
|
| Decision Support Techniques | 4 | 2018 | 1956 | 0.100 |
Why?
|
| Age Factors | 8 | 2018 | 18370 | 0.100 |
Why?
|
| Medicare | 5 | 2023 | 6566 | 0.100 |
Why?
|
| United States | 15 | 2023 | 69872 | 0.100 |
Why?
|
| Minority Groups | 1 | 2018 | 1223 | 0.090 |
Why?
|
| Risk | 2 | 2021 | 9687 | 0.090 |
Why?
|
| Cost Savings | 1 | 2015 | 926 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 7279 | 0.090 |
Why?
|
| Female | 27 | 2023 | 380194 | 0.090 |
Why?
|
| Duodenal Neoplasms | 1 | 2009 | 106 | 0.090 |
Why?
|
| Informed Consent | 1 | 2016 | 995 | 0.090 |
Why?
|
| Poverty | 2 | 2018 | 2660 | 0.080 |
Why?
|
| Medically Uninsured | 1 | 2014 | 853 | 0.080 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 2065 | 0.080 |
Why?
|
| Time Factors | 5 | 2020 | 40075 | 0.080 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2009 | 224 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2021 | 40561 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 547 | 0.070 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 3674 | 0.070 |
Why?
|
| DNA | 2 | 2021 | 7301 | 0.070 |
Why?
|
| Calibration | 1 | 2009 | 816 | 0.070 |
Why?
|
| Adult | 11 | 2023 | 214055 | 0.070 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2009 | 503 | 0.070 |
Why?
|
| Hypercholesterolemia | 2 | 1999 | 1151 | 0.070 |
Why?
|
| SEER Program | 3 | 2018 | 1508 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2011 | 1534 | 0.060 |
Why?
|
| Male | 23 | 2023 | 350118 | 0.060 |
Why?
|
| Lung | 1 | 2023 | 9856 | 0.060 |
Why?
|
| Comorbidity | 4 | 2023 | 10388 | 0.060 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 4258 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2020 | 23338 | 0.060 |
Why?
|
| Population Surveillance | 2 | 2011 | 2616 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2018 | 3749 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 3143 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 11366 | 0.050 |
Why?
|
| Hematologic Tests | 1 | 2023 | 240 | 0.050 |
Why?
|
| Neoplasms | 2 | 2009 | 21683 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 4262 | 0.050 |
Why?
|
| Markov Chains | 2 | 2018 | 969 | 0.050 |
Why?
|
| Naloxone | 1 | 2023 | 367 | 0.050 |
Why?
|
| Fibrin | 1 | 2002 | 506 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 3610 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11524 | 0.040 |
Why?
|
| American Cancer Society | 1 | 2018 | 61 | 0.040 |
Why?
|
| Health Policy | 1 | 2011 | 2661 | 0.040 |
Why?
|
| Incidence | 4 | 2020 | 20947 | 0.040 |
Why?
|
| Weight Loss | 1 | 1999 | 2622 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 20129 | 0.040 |
Why?
|
| Obesity | 2 | 1999 | 12745 | 0.040 |
Why?
|
| Young Adult | 1 | 2021 | 56430 | 0.030 |
Why?
|
| South Carolina | 1 | 2014 | 99 | 0.030 |
Why?
|
| Health Services Research | 2 | 2015 | 1836 | 0.030 |
Why?
|
| Furans | 1 | 2014 | 194 | 0.030 |
Why?
|
| Kallikreins | 1 | 2014 | 258 | 0.030 |
Why?
|
| Hypertension | 2 | 1999 | 8480 | 0.030 |
Why?
|
| Disease Progression | 3 | 2018 | 13284 | 0.030 |
Why?
|
| Body Mass Index | 1 | 1999 | 12720 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 11124 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 11031 | 0.020 |
Why?
|
| Survival Rate | 2 | 2018 | 12788 | 0.020 |
Why?
|
| Phenols | 1 | 2014 | 497 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2023 | 5985 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 9959 | 0.020 |
Why?
|
| Public Health | 1 | 2023 | 2603 | 0.020 |
Why?
|
| Models, Biological | 2 | 2018 | 9583 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2012 | 981 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3479 | 0.020 |
Why?
|
| Models, Econometric | 1 | 1999 | 218 | 0.020 |
Why?
|
| Capsule Endoscopy | 1 | 2010 | 125 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 6895 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 1681 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6538 | 0.020 |
Why?
|
| Risk Factors | 3 | 2023 | 72290 | 0.020 |
Why?
|
| Cause of Death | 1 | 2018 | 3584 | 0.020 |
Why?
|
| Research | 1 | 2016 | 1999 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8642 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2020 | 8324 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 2728 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 3507 | 0.020 |
Why?
|
| Organizational Policy | 1 | 2008 | 429 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 1254 | 0.020 |
Why?
|
| Reimbursement Mechanisms | 1 | 2010 | 670 | 0.020 |
Why?
|
| Coronary Disease | 2 | 1999 | 6077 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 2494 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 2013 | 1206 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 1999 | 15165 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2008 | 1184 | 0.010 |
Why?
|
| Mammography | 1 | 2014 | 2476 | 0.010 |
Why?
|
| Pandemics | 1 | 2023 | 8388 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 3158 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2011 | 1928 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 1999 | 1504 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2002 | 6487 | 0.010 |
Why?
|
| Mortality | 1 | 2013 | 2864 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 1405 | 0.010 |
Why?
|
| Infant | 2 | 2023 | 35136 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 15076 | 0.010 |
Why?
|
| Prevalence | 1 | 2019 | 15226 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 2541 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 9239 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2013 | 9849 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 5137 | 0.010 |
Why?
|
| Health Surveys | 1 | 2011 | 4037 | 0.010 |
Why?
|
| Solubility | 1 | 2002 | 1085 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 2212 | 0.010 |
Why?
|
| Cost of Illness | 1 | 1999 | 1859 | 0.010 |
Why?
|
| Thrombophilia | 1 | 2002 | 305 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2011 | 3743 | 0.010 |
Why?
|
| Carcinoma | 1 | 2010 | 2375 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 2716 | 0.010 |
Why?
|
| Reference Standards | 1 | 2002 | 1025 | 0.010 |
Why?
|
| Contrast Media | 1 | 2011 | 5300 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2011 | 10252 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2018 | 63114 | 0.010 |
Why?
|
| Troponin T | 1 | 2002 | 754 | 0.010 |
Why?
|
| Decision Making | 1 | 2011 | 3887 | 0.010 |
Why?
|
| Dengue | 1 | 1980 | 256 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 19905 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39050 | 0.010 |
Why?
|
| Prognosis | 2 | 2009 | 29063 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 1999 | 11725 | 0.010 |
Why?
|
| Chest Pain | 1 | 2002 | 1114 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 3870 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2008 | 4371 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 1980 | 1772 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 77449 | 0.010 |
Why?
|
| Quality of Life | 1 | 2009 | 12804 | 0.000 |
Why?
|
| Stroke | 1 | 1999 | 9981 | 0.000 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 1980 | 77 | 0.000 |
Why?
|
| Malaysia | 1 | 1980 | 92 | 0.000 |
Why?
|
| Culicidae | 1 | 1980 | 105 | 0.000 |
Why?
|
| Insect Vectors | 1 | 1980 | 134 | 0.000 |
Why?
|
| Dengue Virus | 1 | 1980 | 204 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1980 | 3176 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1980 | 41006 | 0.000 |
Why?
|
| Child | 1 | 1980 | 77709 | 0.000 |
Why?
|
| Adolescent | 1 | 1980 | 85781 | 0.000 |
Why?
|
Concepts
(184)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(21)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_